The company reported the results from the WM cohort & P-I/II trial evaluating MB-106 in patients with B-NHLs & CLL at Fred Hutchinson Cancer Center. MB-106 dose levels will be tested in each arm in the P-I study using a 3+3 design & the therapy is being developed in collaboration with Mustang and Fred Hutch
As of Sept 2022, the results showed ORR (96%), a CR rate of 75% in a wide range of hematologic malignancies, 100% ORR & 2 in CR with WM, and 12 experienced CR for ≥12mos. (10 ongoing); 4 with CR for ≥2yrs. & the longest patient with CR @33mos., 6 with PR improved to CR, and all remain in ongoing CR
3 patients responded to treatment who were prior treated with CD-19 CAR T cell therapy, had high efficacy and a favorable safety profile with no CRS or ICANS ≥ grade 3
Ref: GlobeNewswire | Image: Mustang Bio
